Hainan Novozan exits Logilet (UK) Limited with 65% stake transferred

Published

Hainan Novozan Biotechnology exited Logilet (UK) Limited, a point-of-care DNA diagnostics firm, transferring its 65% ordinary holding. The filing does not name the recipient.

Xiamen Judi Gongying Enterprise Management Partnership (Limited Partnership) entered with a 3.8% preference holding.

Andon Hong Kong Co., Limited entered with a 3.5% preference holding.

Nanjing Zijin Biomedical Industry Investment Fund Partnership (Limited Partnership) entered with a 2.5% preference holding.

Huaxi Yinfeng Investment Co., Limited entered with a 2.5% preference holding.

The four new non-individual holders and larger register suggest fresh funding. Filed on 20 September 2026, covering 13 August to 20 September 2026.

Shareholder data

Source: Companies House confirmation statement (CS01) — period to , filed .

Changes in this confirmation statement

TypeShareholderSharesChangeShare classes
ExitedHAINAN NOVOZAN BIOTECHNOLOGY CO., LTD.0
ORD 0
New shareholderXIAMEN JUDI GONGYING ENTERPRISE MANAGEMENT PARTNERSHIP (LIMITED PARTNERSHIP)46,247
PREFERENCE 46,247
New shareholderANDON HONG KONG CO., LIMITED43,243
PREFERENCE 43,243
New shareholderHUAXI YINFENG INVESTMENT CO., LIMITED30,831
PREFERENCE 30,831
New shareholderNANJING ZIJIN BIOMEDICAL INDUSTRY INVESTMENT FUND PARTNERSHIP (LIMITED PARTNERSHIP)30,831
PREFERENCE 30,831

Current shareholders (7)

ShareholderTotal sharesShare classes
HAINAN VAZYME BIOTECH CO., LTD.701,415
ORD 701,415
NEWRGY CAPITAL LIMITED269,775
ORD 269,775
HONOR CAPITAL LIMITED107,910
ORD 107,910
XIAMEN JUDI GONGYING ENTERPRISE MANAGEMENT PARTNERSHIP (LIMITED PARTNERSHIP)46,247
PREFERENCE 46,247
ANDON HONG KONG CO., LIMITED43,243
PREFERENCE 43,243
NANJING ZIJIN BIOMEDICAL INDUSTRY INVESTMENT FUND PARTNERSHIP (LIMITED PARTNERSHIP)30,831
PREFERENCE 30,831
HUAXI YINFENG INVESTMENT CO., LIMITED30,831
PREFERENCE 30,831

Share this

Contact the editorial team at editorial@fundingspotter.com